ValuEngine downgraded shares of Kindred Biosciences (NASDAQ:KIN) from a hold rating to a sell rating in a research report report published on Wednesday, January 3rd.
KIN has been the subject of several other research reports. B. Riley set a $11.00 price objective on shares of Kindred Biosciences and gave the stock a buy rating in a research report on Tuesday, December 5th. Zacks Investment Research raised shares of Kindred Biosciences from a hold rating to a buy rating and set a $8.25 target price for the company in a report on Wednesday, September 27th. CL King assumed coverage on shares of Kindred Biosciences in a report on Wednesday, December 27th. They set a neutral rating for the company. BMO Capital Markets reaffirmed a hold rating on shares of Kindred Biosciences in a report on Friday, December 22nd. Finally, Aegis reaffirmed a buy rating on shares of Kindred Biosciences in a report on Friday, December 15th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $9.63.
Kindred Biosciences (NASDAQ:KIN) traded up $0.05 during mid-day trading on Wednesday, reaching $8.95. The company had a trading volume of 97,000 shares, compared to its average volume of 67,637. Kindred Biosciences has a fifty-two week low of $5.00 and a fifty-two week high of $9.80. The firm has a market capitalization of $249.15, a P/E ratio of -7.65 and a beta of 0.18.
Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. equities analysts predict that Kindred Biosciences will post -1.19 EPS for the current fiscal year.
In other Kindred Biosciences news, Director Raymond Townsend sold 6,419 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $9.45, for a total transaction of $60,659.55. Following the sale, the director now directly owns 18,419 shares of the company’s stock, valued at approximately $174,059.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 19.10% of the company’s stock.
Hedge funds have recently modified their holdings of the company. General American Investors Co. Inc. acquired a new position in Kindred Biosciences in the 3rd quarter valued at about $5,232,000. AJO LP acquired a new position in Kindred Biosciences in the 2nd quarter valued at about $2,407,000. Vanguard Group Inc. grew its stake in Kindred Biosciences by 57.7% in the 2nd quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after buying an additional 272,612 shares during the last quarter. State Street Corp acquired a new position in Kindred Biosciences in the 2nd quarter valued at about $2,209,000. Finally, Pacific Grove Capital LP acquired a new position in Kindred Biosciences in the 3rd quarter valued at about $1,475,000. 66.79% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2018/01/12/kindred-biosciences-kin-downgraded-by-valuengine-to-sell.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.